Clincosm LogoSign in Get a demo

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Sponsor
Meir Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT01270399
Collaborator
(none)
20
Enrollment
1
Location
24
Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed.

Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included).

The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
    Study Start Date :
    Jan 1, 2011
    Anticipated Primary Completion Date :
    Jan 1, 2013
    Anticipated Study Completion Date :
    Jan 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    malignant neoplasm's cells
    natural cells

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL SURGICAL TREATMENT
      Exclusion Criteria:
      • PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE SURGERY

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Meir Medical Center Kfar Saba Israel

      Sponsors and Collaborators

      • Meir Medical Center

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Meir Medical Center
      ClinicalTrials.gov Identifier:
      NCT01270399
      Other Study ID Numbers:
      • MMC10160-2010CTIL
      First Posted:
      Jan 5, 2011
      Last Update Posted:
      Oct 30, 2012
      Last Verified:
      Mar 1, 2012
      Additional relevant MeSH terms:
      Lung Neoplasms

      Study Results

      No Results Posted as of Oct 30, 2012